help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-2036
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/3/1172    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khamaisi, M.
Right arrow Articles by Elad, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khamaisi, M.
Right arrow Articles by Elad, S.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Diabetes
*Osteonecrosis
Related Collections
Right arrow Calcium and Bone Metabolism
Right arrow Diabetes and Insulin
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 3 1172-1175
Copyright © 2007 by The Endocrine Society


BRIEF REPORT

Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis

Mogher Khamaisi, Eran Regev, Noam Yarom, Batia Avni, Eran Leitersdorf, Itamar Raz and Sharon Elad

Department of Internal Medicine B and the Diabetes Center (M.K., E.L., I.R.), Hebrew University-Hadassah Medical Center, Departments of Oral and Maxillofacial Surgery (E.R.) and Oral Medicine (S.E.), Hebrew University-Hadassah School of Dental Medicine, and Department of Hematology (B.A., S.E.), Hadassah Medical Center, Jerusalem 91120, Israel; and Department of Oral Pathology and Oral Medicine (N.Y.), The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv 69978, Israel

Address all correspondence and requests for reprints to: Mogher Khamaisi, M.D., Ph.D., Department of Internal Medicine B and the Diabetes Center, Hebrew University-Hadassah Medical Center, Kiryat Hadassah, P.O. Box 12000, Jerusalem 91120, Israel. E-mail: murir{at}hadassah.org.il; or mogher{at}bgumail.bgu.ac.il.

Context: Bisphosphonate-related osteonecrosis (BON) of the jaws is a newly identified condition for which the exact mechanism involved in its pathogenesis remains obscure.

Objective: The objective of the study was to evaluate whether diabetes mellitus (DM) may be a contributing factor in the development of BON.

Design: From 2004 to 2006, 31 patients were diagnosed with BON. The diagnosis of BON was based on the medical and dental history of each patient as well as the observation of clinical signs and symptoms of this pathological process. DM was based on two consecutive fasting blood glucose levels above 7 mmol/liter.

Setting: The study was completed in the Hebrew University-Hadassah Hospital referral center.

Results: Of the 31 patients with BON, 18 (58%) were found to have DM or impaired fasting glucose. The proportion of diabetic patients was much higher than expected relative to the incidence of DM in the general population (14%) and compared with the proportion of diabetic patients in a control group of oncological patients treated with bisphosphonates and without BON (12%) (P = 0.00003).

Conclusions: This finding indicates that DM may be a risk factor for BON and that DM patients treated with bisphosphonates should be carefully monitored. We discuss here the bone metabolic pathways characteristic of DM patients and the way in which these pathways can augment the effects of bisphosphonates.




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
M. Khamaisi and S. Elad
Re: Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis
J Natl Cancer Inst, January 16, 2008; 100(2): 155 - 155.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. S. Wilkinson, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin
Response: Re: Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis
J Natl Cancer Inst, January 16, 2008; 100(2): 155 - 156.
[Full Text] [PDF]


Home page
Journal of the American Dental AssociationHome page
J. T. Grbic, R. Landesberg, S.-Q. Lin, P. Mesenbrink, I. R. Reid, P.-C. Leung, N. Casas, C. P. Recknor, Y. Hua, P. D. Delmas, et al.
Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial
J Am Dent Assoc, January 1, 2008; 139(1): 32 - 40.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. J. Favus
Diabetes and the Risk of Osteonecrosis of the Jaw
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 817 - 818.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society